Design Therapeutics
DSGN
88 hedge funds and large institutions have $85.5M invested in Design Therapeutics in 2023 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 14 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 25
10% more capital invested
Capital invested by funds: $77.6M → $85.5M (+$7.92M)
1% more funds holding
Funds holding: 87 → 88 (+1)
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.1% less ownership
Funds ownership: 58.7% → 57.61% (-1.1%)
24% less call options, than puts
Call options by funds: $253K | Put options by funds: $335K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$2.36M |
| 2 |
AC
Almitas Capital
Santa Monica,
California
|
+$2.35M |
| 3 |
Morgan Stanley
New York
|
+$1.66M |
| 4 |
Goldman Sachs
New York
|
+$1.33M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$5.93M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.42M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$2.12M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.99M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
-$1.61M |
DSGN Hedge Fund Activity: Q4 2023 in Review
88 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q4 2023, worth a combined $85.5M — up 10% from $77.6M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new DSGN positions and 14 closed out — a net gain of 1 holder — while 36 added to existing stakes and 25 trimmed.
The largest buyer was BML Capital Management, opening a new position worth an estimated $2.36M. The largest seller was RTW Investments, exiting entirely with an estimated $5.93M sold.
- 88 institutional investors held Design Therapeutics (DSGN) as of Q4 2023, up from 87 in Q3 2023.
- Funds reported $85.5M of Design Therapeutics stock for Q4 2023, up 10% quarter-over-quarter.
- 15 funds opened new Design Therapeutics positions in Q4 2023 and 14 closed out, a net change of +1 holder.
- The largest Design Therapeutics buyer in Q4 2023 was BML Capital Management, an estimated $2.36M added.
- The largest Design Therapeutics seller in Q4 2023 was RTW Investments, an estimated $5.93M sold.
Based on aggregated 13F filings for Q4 2023.